Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies and diagnostics for the treatment and prevention of human diseases. The company's portfolio includes products for immunology, rare disease, infectious disease, and central nervous system conditions. It is currently developing multiple products, including TNX-1500 for organ transplant rejection and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox and monkeypox prevention.